Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Helene Lasolle; Christine Cortet; Frederic Castinetti; Lucie Cloix; Philippe Caron; Brigitte Delemer; Rachel Desailloud; Christel Jublanc; Christine Lebrun-Frenay; Jean-Louis Sadoul; Luc Taillandier; Marie Batisse-Lignier; Fabrice Bonnet; Nathalie Bourcigaux; Damien Bresson; Olivier Chabre; Philippe Chanson; Cyril Garcia; Magalie Haissaguerre; Yves Reznik; Sophie Borot; Chiara Villa; Alexandre Vasiljevic; Stephan Gaillard; Emmanuel Jouanneau; Guillaume Assie; Gerald Raverot

doi:10.1530/EJE-16-0979

Article dans une revue

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Helene Lasolle ^{1, 2} Christine Cortet ^{3, 4} Frederic Castinetti ^{5, 6} Lucie Cloix ^{7, 8} Philippe Caron ⁹ Brigitte Delemer ^{10, 11} Rachel Desailloud ¹² Christel Jublanc ¹³ Christine Lebrun-Frenay ^{14, 15} Jean-Louis Sadoul ^{14, 16} Luc Taillandier ¹⁷ Marie Batisse-Lignier ^{18, 19} Fabrice Bonnet ²⁰ Nathalie Bourcigaux ²¹ Damien Bresson ²² Olivier Chabre ²³ Philippe Chanson ^{24, 25} Cyril Garcia ²⁶ Magalie Haissaguerre ^{27, 28} Yves Reznik ²⁹ Sophie Borot ^{30, 31} Chiara Villa ^{32, 33} Alexandre Vasiljevic ³⁴ Stephan Gaillard ³² Emmanuel Jouanneau ^{1, 2} Guillaume Assie ^{35, 33} Gerald Raverot ^{34, 1}

1 UCBL - Université Claude Bernard Lyon 1

2 HCL - Hospices Civils de Lyon

3 Hôpital Claude Huriez [Lille]

4 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]

5 TIMONE - Hôpital de la Timone [CHU - APHM]

6 CHU Marseille

7 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours

8 Hôpital Bretonneau

9 CHU Toulouse [Toulouse]

10 Hôpital universitaire Robert Debré [Reims]

11 CHU Reims - Centre Hospitalier Universitaire de Reims

12 CHU Amiens-Picardie

13 CHU Pitié-Salpêtrière [AP-HP]

14 CHU Nice - Centre Hospitalier Universitaire de Nice

15 CHU - Hôpital Pasteur [Nice]

16 Hôpital l'Archet

17 CHU Poitiers - Centre hospitalier universitaire de Poitiers

18 CHU Clermont-Ferrand

19 CHU Gabriel Montpied [Clermont-Ferrand]

20 CHU Pontchaillou [Rennes]

21 CHU Saint-Antoine [AP-HP]

22 Hôpital Lariboisière-Fernand-Widal [APHP]

23 CHU - Centre Hospitalier Universitaire [Grenoble]

24 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)

25 Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique

26 Hôpital d'Instruction des Armées Begin

27 Hôpital Haut-Lévêque [CHU Bordeaux]

28 CHU Bordeaux [Bordeaux]

29 Service Endocrinologie - Diabétologie [CHU Caen]

30 Service de Diabétologie - Endocrinologie [CHRU Besançon]

31 Hôpital JeanMinjoz

32 Hôpital Foch [Suresnes]

33 IC UM3 (UMR 8104 / U1016) - Institut Cochin

34 GHE - Groupement Hospitalier Lyon-Est

35 Hôpital Cochin [AP-HP]

Abstract : Objectives: Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival. Design: Multicenter retrospective study by members of the French Society of Endocrinology. Methods: Forty-three patients (14 women) treated with TMZ between 2006 and 2016 were included. Most tumors were corticotroph (n = 23) or lactotroph (n = 13), and 14 were carcinomas. Clinical/pathological characteristics of PT, as well as data from treatment evaluation and from the last follow-up were recorded. A partial response was considered as a decrease in the maximal tumor diameter by more than 30% and/or in the hormonal rate by more than 50% at the end of treatment. Results: The median treatment duration was 6.5 cycles (range 2-24), using a standard regimen for most and combined radiotherapy for six. Twenty-two patients (51.2%) were considered as responders. Silent tumor at diagnosis was associated with a poor response. The median follow-up after the end of treatment was 16 months (0-72). Overall survival was significantly higher among responders (P = 0.002); however, ten patients relapsed 5 months (0-57) after the end of TMZ treatment, five in whom TMZ was reinitiated without success. Discussion: Patients in our series showed a 51.2% response rate to TMZ, with an improved survival among responders despite frequent relapses. Our study highlights the high variability and lack of standardization of treatment protocols.

Type de document :

Article dans une revue

Domaine :

Sciences du Vivant [q-bio]

Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03555800
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : jeudi 3 février 2022 - 18:26:30
Dernière modification le : vendredi 20 mai 2022 - 11:06:36

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Métriques

19

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Partager

Métriques

19